Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study

Basit Öğe Kaydı
dc.contributor.authorBasoglu, Tugba
dc.contributor.authorSakin, Abdullah
dc.contributor.authorErol, Cihan
dc.contributor.authorOzden, Ercan
dc.contributor.authorcabuk, Devrim
dc.contributor.authorCilbir, Ebru
dc.contributor.authorTataroglu ozyukseler, Deniz
dc.date.accessioned2024-02-23T14:20:31Z
dc.date.available2024-02-23T14:20:31Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractNeoadjuvant chemotherapy (NACT) in gastroesophageal junction (GEJ) and gastric cancer (GC) was shown to improve survival in recent studies. We aimed to share our real-life experience of patients who received NACT to compare the efficacy and toxicity profile of different chemotherapy regimens in our country. This retrospective multicentre study included locally advanced GC and GEJ cancer patients who received NACT between 2007 and 2021. Relation between CT regimens and pathological evaluation were analysed. A total of 794 patients from 45 oncology centers in Turkey were included. Median age at the time of diagnosis was 60 (range: 18-86). Most frequent NACT regimens used were FLOT (65.4%), DCF (17.4%) and ECF (8.1%), respectively. In the total study group, pathological complete remission (pCR) rate was 7.2%, R0 resection rate 86.4%, and D2 dissection rate was 66.8%. Rate of pCR and near-CR (24%), and R0 resection (84%) were numerically higher in FLOT arm (p > 0.05). Patients who received FLOT had also higher chemotherapy-related toxicity rate compared to patients who received other regimens (p > 0.05). Median follow-up time was 16 months (range: 1-154 months). Estimated median overall survival (OS) was 58.4months (95% CI: 35.2-85.7) and disease-free survival (DFS) was 50.7 months (95% CI: 25.4-75.9). The highest 3-year estimated OS rate was also shown in FLOT arm (68%). We still do not know which NACT regimen is the best choice for daily practice. Clinicians should tailor treatment regimens according to patients' multifactorial status and comorbidities for to obtain best outcomes. Longer follow-up period needs to validate our results.en_US
dc.identifier.doi10.1080/1120009X.2022.2073159
dc.identifier.endpage149en_US
dc.identifier.issn1120-009X
dc.identifier.issn1973-9478
dc.identifier.issue2en_US
dc.identifier.pmid35579894en_US
dc.identifier.scopus2-s2.0-85130589575en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage142en_US
dc.identifier.urihttps://doi.org/10.1080/1120009X.2022.2073159
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13189
dc.identifier.volume35en_US
dc.identifier.wosWOS:000796893200001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal Of Chemotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGastric Canceren_US
dc.subjectGastroesophageal Junction Canceren_US
dc.subjectNeoadjuvant Chemotherapyen_US
dc.titleReal life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu